Ceftobiprole: Difference between revisions
m (Protected "Ceftobiprole": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
m (Bot: Automated text replacement (-{{SIB}} + & -{{EH}} + & -{{EJ}} + & -{{Editor Help}} + & -{{Editor Join}} +)) |
||
| Line 25: | Line 25: | ||
}} | }} | ||
{{SI}} | {{SI}} | ||
'''Ceftobiprole''' is an experimental [[cephalosporin]] [[antibiotic]] with activity against [[Methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']].<ref>{{cite journal |author=Yun HC, Ellis MW, Jorgensen JH |title=Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees |journal= |volume= |issue= |pages= |year=2007 |pmid=17911001 |doi=10.1016/j.diagmicrobio.2007.06.023}}</ref> It was discovered by [[Basilea Pharmaceutica]] and is being developed by [[Johnson & Johnson Pharmaceutical Research and Development]].<ref>[http://www.basilea.com/template_loader.php?tplpage_id=160 Basilea.com]</ref> | '''Ceftobiprole''' is an experimental [[cephalosporin]] [[antibiotic]] with activity against [[Methicillin-resistant Staphylococcus aureus|methicillin-resistant ''Staphylococcus aureus'']].<ref>{{cite journal |author=Yun HC, Ellis MW, Jorgensen JH |title=Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees |journal= |volume= |issue= |pages= |year=2007 |pmid=17911001 |doi=10.1016/j.diagmicrobio.2007.06.023}}</ref> It was discovered by [[Basilea Pharmaceutica]] and is being developed by [[Johnson & Johnson Pharmaceutical Research and Development]].<ref>[http://www.basilea.com/template_loader.php?tplpage_id=160 Basilea.com]</ref> | ||
| Line 34: | Line 34: | ||
[[Category:cephalosporin antibiotics]] | [[Category:cephalosporin antibiotics]] | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} | ||
Revision as of 23:36, 8 August 2012
|
WikiDoc Resources for Ceftobiprole |
|
Articles |
|---|
|
Most recent articles on Ceftobiprole Most cited articles on Ceftobiprole |
|
Media |
|
Powerpoint slides on Ceftobiprole |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Ceftobiprole at Clinical Trials.gov Clinical Trials on Ceftobiprole at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Ceftobiprole
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Ceftobiprole Discussion groups on Ceftobiprole Patient Handouts on Ceftobiprole Directions to Hospitals Treating Ceftobiprole Risk calculators and risk factors for Ceftobiprole
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Ceftobiprole |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Ceftobiprole is an experimental cephalosporin antibiotic with activity against methicillin-resistant Staphylococcus aureus.[1] It was discovered by Basilea Pharmaceutica and is being developed by Johnson & Johnson Pharmaceutical Research and Development.[2]
References
- ↑ Yun HC, Ellis MW, Jorgensen JH (2007). "Activity of ceftobiprole against community-associated methicillin-resistant Staphylococcus aureus isolates recently recovered from US military trainees". doi:10.1016/j.diagmicrobio.2007.06.023. PMID 17911001.
- ↑ Basilea.com